Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models

References

• Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275:L843 - 51; PMID: 9815100
   PubMedGoogle Scholar
• Sternberg PW, Schmid SL. Caveolin, cholesterol and Ras signalling. Nat Cell Biol 1999; 1:E35 - 7; http://dx.doi.org/10.1038/10028; PMID: 10559891
   PubMedGoogle Scholar
• Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008; 84:177 - 89; http://dx.doi.org/10.1080/09553000701745293; PMID: 18300018
   PubMed Web of Science ®Google Scholar
• Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288:C494 - 506; http://dx.doi.org/10.1152/ajpcell.00458.2004; PMID: 15692148
   PubMed Web of Science ®Google Scholar
• Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 2010; 13:6 - 11; http://dx.doi.org/10.1038/pcan.2009.29; PMID: 19581923
   PubMed Web of Science ®Google Scholar
• Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005; 280:25134 - 45; http://dx.doi.org/10.1074/jbc.M501186200; PMID: 15802273
   PubMed Web of Science ®Google Scholar
• Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, et al. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 2009; 7:1446 - 55; http://dx.doi.org/10.1158/1541-7786.MCR-09-0071; PMID: 19737975
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al, American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596 - 605; http://dx.doi.org/10.1200/JCO.2006.10.1949; PMID: 17404365
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513 - 20; http://dx.doi.org/10.1056/NEJMoa041318; PMID: 15470214
   PubMed Web of Science ®Google Scholar
• Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009; 7:1781 - 91; http://dx.doi.org/10.1158/1541-7786.MCR-09-0255; PMID: 19903767
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61:4386 - 92; PMID: 11389065
   PubMed Web of Science ®Google Scholar
• Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23:9389 - 404; http://dx.doi.org/10.1128/MCB.23.24.9389-9404.2003; PMID: 14645548
   PubMed Web of Science ®Google Scholar
• Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 2009; 8:2286 - 96; PMID: 19923922
   PubMed Web of Science ®Google Scholar
• Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61:3882 - 5; PMID: 11358800
   PubMed Web of Science ®Google Scholar
• Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer 2008; 122:520 - 5; http://dx.doi.org/10.1002/ijc.23142; PMID: 17943731
   PubMed Web of Science ®Google Scholar
• Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62:2423 - 9; PMID: 11956106
   PubMed Web of Science ®Google Scholar
• Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68:731 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-07-2668; PMID: 18245473
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658 - 61; http://dx.doi.org/10.1021/jm049486a; PMID: 15615512
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65:9185 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-1731; PMID: 16230377
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471 - 8; PMID: 12748309
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465 - 76; PMID: 14654525
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597 - 605; http://dx.doi.org/10.1182/blood-2002-07-2307; PMID: 12531805
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327 - 37; PMID: 12538485
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734 - 45; http://dx.doi.org/10.1038/nrd2380; PMID: 17690708
   PubMed Web of Science ®Google Scholar
• Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9:3653 - 9; PMID: 14506154
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68:3323 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-07-2997; PMID: 18451159
   PubMed Web of Science ®Google Scholar
• Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27:6365 - 75; http://dx.doi.org/10.1038/onc.2008.250; PMID: 18679417
   PubMed Web of Science ®Google Scholar
• Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12:4872 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-06-0417; PMID: 16914574
   PubMed Web of Science ®Google Scholar
• Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9:66 - 76; PMID: 19149483
   PubMed Web of Science ®Google Scholar
• Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010; 6:1175 - 93; http://dx.doi.org/10.1517/17425255.2010.506873; PMID: 20684746
   PubMed Web of Science ®Google Scholar
• Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011; 38:Suppl 1 S10 - 9; http://dx.doi.org/10.1053/j.seminoncol.2011.01.018; PMID: 21419931
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010; 11:992 - 1000; http://dx.doi.org/10.1016/S1470-2045(10)70088-7; PMID: 20667780
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets 2009; 9:738 - 47; http://dx.doi.org/10.2174/156800909789271530; PMID: 19754358
   PubMed Web of Science ®Google Scholar
• Abouantoun TJ, Castellino RC, MacDonald TJ. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 2011; 101:215 - 26; http://dx.doi.org/10.1007/s11060-010-0259-9; PMID: 20524040
   PubMed Web of Science ®Google Scholar
• Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67:2226 - 38; http://dx.doi.org/10.1158/0008-5472.CAN-06-3633; PMID: 17332353
   PubMed Web of Science ®Google Scholar
• Aoki T, Nomura R, Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 1999; 253:629 - 36; http://dx.doi.org/10.1006/excr.1999.4652; PMID: 10585286
   PubMed Web of Science ®Google Scholar
• Zundel W, Swiersz LM, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol 2000; 20:1507 - 14; http://dx.doi.org/10.1128/MCB.20.5.1507-1514.2000; PMID: 10669728
   PubMed Web of Science ®Google Scholar
• Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, et al. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer 2009; 125:1514 - 22; http://dx.doi.org/10.1002/ijc.24451; PMID: 19521982
   PubMed Web of Science ®Google Scholar
• Zhang B, Peng F, Wu D, Ingram AJ, Gao B, Krepinsky JC. Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells. Cell Signal 2007; 19:1690 - 700; http://dx.doi.org/10.1016/j.cellsig.2007.03.005; PMID: 17446044
   PubMed Web of Science ®Google Scholar
• Percy CJ, Pat BK, Healy H, Johnson DW, Gobe GC. Phosphorylation of caveolin-1 is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells. Pathology 2008; 40:694 - 701; http://dx.doi.org/10.1080/00313020802436402; PMID: 18985523
   PubMed Web of Science ®Google Scholar
• Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68:8210 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-08-0343; PMID: 18922892
   PubMed Web of Science ®Google Scholar
• Schlegel A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem 2001; 276:4398 - 408; http://dx.doi.org/10.1074/jbc.M005448200; PMID: 11078729
   PubMed Web of Science ®Google Scholar
• Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; 284:34211 - 22; http://dx.doi.org/10.1074/jbc.M109.041152; PMID: 19801663
   PubMed Web of Science ®Google Scholar
• Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69:5601 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-3860; PMID: 19549916
   PubMed Web of Science ®Google Scholar
• Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci 2004; 117:5343 - 51; http://dx.doi.org/10.1242/jcs.01420; PMID: 15466889
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148 - 59; http://dx.doi.org/10.1200/JCO.2007.12.4487; PMID: 18309951
   PubMed Web of Science ®Google Scholar
• Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007; 8:R255; http://dx.doi.org/10.1186/gb-2007-8-11-r255; PMID: 18047674
   PubMedGoogle Scholar